10-Q: Charlies Holdings Reports Q1 2026 Results, Revenue Surges 204%

Charlies Holdings, Inc. reported a significant increase in revenue for the first quarter of 2026, driven by strong sales in its nicotine-based and alternative alkaloid products, despite an overall net loss.

Summary

• Charlies Holdings, Inc. reported a substantial 204.4% increase in revenue for the first quarter of 2026, reaching $4.8 million compared to $1.6 million in the same period of 2025.
• The company incurred a net loss of $1.05 million for the quarter, an improvement from the $1.22 million net loss in Q1 2025.
• Operating costs and expenses increased by 70.4% to $2.16 million, primarily due to higher general and administrative expenses.
• The company's working capital improved to $4.84 million as of March 31, 2026, up from $3.14 million at the end of 2025.
• Significant debt was repaid or converted to equity during the quarter, strengthening the company's financial position.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with strong revenue growth and improved net loss, but significant regulatory risks and ongoing operational losses remain key concerns.

Positives

• Revenue surged by 204.4% to $4.8 million in Q1 2026, driven by strong sales of nicotine-based and alternative alkaloid products.
• Net loss improved to $1.05 million from $1.22 million in the prior year's quarter.
• Working capital increased to $4.84 million as of March 31, 2026.
• The company completed a private placement on February 13, 2026, raising $710,000 and satisfying $200,000 in debt.
• The company completed another private placement on May 20, 2026, raising $1.75 million and satisfying $1 million in debt.
• The company's August 2025 Note financing was amended to extend the maturity date to June 1, 2027.
• The company's July 2023 Note Financing was fully satisfied as of March 31, 2026.
• The company's April 2022 Note was fully satisfied as of March 31, 2026.

Negatives

• The company reported a net loss of $1.05 million for the quarter.
• Loss from operations increased to $975,000 from $879,000 in the prior year's quarter.
• General and administrative expenses increased by 60.0% to $1.74 million.
• Sales and marketing expenses increased by 121.4% to $383,000.
• Research and development expenses increased by 466.7% to $34,000.
• The company received a Marketing Denial Order (MDO) from the FDA on April 1, 2026, for certain PMTA products, which is being challenged.
• The company received an MDO from the FDA on October 28, 2025, for certain PMTAs, which was stayed pending judicial review.

Risks

• The company operates in a highly regulated environment with potential for rapid changes in laws and regulations impacting product sales.
• State and local governments are considering restrictions on flavored e-cigarettes, which could limit markets.
• The FDA's plan to reduce nicotine levels in cigarettes could impact the industry.
• New laws or regulations concerning nicotine, flavored e-cigarette liquid, and ENDS products could significantly limit sales, increase compliance costs, or require changes in labeling and distribution.
• Bans on flavored e-cigarettes directly limit the markets in which the company can sell its products.
• The company is seeking marketing authorization for certain tobacco-derived nicotine e-liquid products, but approval is not assured.
• The FDA issued a Marketing Denial Order (MDO) on April 1, 2026, for certain PMTA products, which the company is challenging.
• The FDA issued an MDO on October 28, 2025, for certain PMTAs, which is currently under a stay pending judicial review.
• The company's synthetic nicotine products are subject to FDA rules, and PMTAs were filed for these products.
• The company launched new disposable vape products under the SBX brand, which it believes are not subject to FDA review due to the active ingredient Metatine, but regulatory changes could impact this.
• If the FDA deems Metatine products as tobacco products, they could be subject to enforcement actions for lack of premarket authorization.
• FDA regulatory initiatives and enforcement authority are unpredictable and evolving.
• The company has a concentration of inventory purchases from a few vendors.
• The company has a concentration of accounts receivable from a few customers.
• The company is involved in a patent dispute between Juul Labs and Glas, Inc., which could impact the market for flavored ENDS products.
• The company's lease for its corporate headquarters is with related parties (former CEO and COO).

Future Outlook

The company plans to grow sales and retail distribution through chain convenience stores, utilize IKE age-gating technology to amend PMTAs and demonstrate product appropriateness for public health, introduce new 75K Puff disposable devices, form strategic partnerships to monetize remaining PMTA-submitted products, grow international sales, and uplist to a national securities exchange.

Management Comments

• Management believes the Company is adequately capitalized to support its operations and meet its obligations as they come due for at least the next twelve months.
• Management evaluated whether conditions could raise a substantial doubt about the Company's ability to continue as a going concern.
• Management has implemented and continues to execute on initiatives designed to enhance operating performance and liquidity, including focusing on growth in non-combustible, alternative alkaloid products, advancing regulatory approval efforts, and developing intellectual property.
• The Company believes that demonstrating robust age-gating capabilities through IKE technology could support a showing to the FDA that its flavored ENDS products are 'appropriate for the protection of public health,' consistent with the PMTA review standard.
• The Company believes a successful regulatory outcome would be transformational for Charlie's flavored product portfolio and could establish a meaningful precedent for the broader vapor products industry.

Industry Context

StockSavvy.ai notes that Charlies Holdings is navigating a complex and evolving regulatory landscape within the vapor products industry. The company's strategy of developing both FDA-compliant nicotine products and non-nicotine alternatives, coupled with investments in age-gating technology, reflects a common approach to mitigate regulatory risk and capture market share in a sector facing increasing scrutiny.

Comparison to Industry Standards

• The company's revenue growth of 204.4% significantly outpaces the general market, but is within the high-growth range seen in specialized consumer product sectors.
• The net loss, while improved, indicates ongoing investment in growth and regulatory compliance, a common characteristic of companies in the early to mid-stages of development within the highly regulated vapor industry.
• The company's focus on PMTA applications and regulatory compliance is a critical industry standard, as the FDA's oversight of ENDS products is a defining factor for market access and long-term viability.
• The development of alternative alkaloid products (like Metatine) represents an innovative approach to circumventing current nicotine-specific regulations, a strategy that some other emerging players in the vapor space may also be exploring.

Legal Proceedings

• As of the date of the filing, the Company is not a party to any material legal or administrative proceedings.
• There are no proceedings in which any of the Company's directors, executive officers or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to the Company's interest.
• The Company may be involved in various claims and counterclaims and legal actions arising in the ordinary course of business.

Related Party Transactions

• The Williamsville Lease is with Henry Sicignano Jr., a relative of the Company's President.
• The corporate headquarters lease in Costa Mesa, California is with Brandon Stump (former CEO), Ryan Stump (COO), and Keith Stump (former Board member).
• Total rent paid to related parties for the years ended December 31, 2025 and 2024 was approximately $275,000 and $275,000, respectively.
• Management and directors purchased shares in the February 13, 2026 private placement: Michael King (500,000 shares), Edward Carmines (250,000 shares), Ryan Stump (250,000 shares), Henry Sicignano III (250,000 shares), Matthew Montesano (100,000 shares).

Stakeholder Impact

• Shareholders: The company's strategy includes efforts to uplist to a national securities exchange, which could improve liquidity and market capitalization. However, ongoing net losses and regulatory risks present challenges.
• Employees: The company has seen increases in non-commission wages and benefits to support revenue growth, indicating investment in its workforce.
• Customers: The company is focusing on providing adult smokers with alternatives to combustible cigarettes and is developing products with award-winning flavors.
• Suppliers: The company has a concentration of inventory purchases from a few vendors, which could pose a risk if supply chains are disrupted.
• Creditors: The company has been actively reducing outstanding debt through equity raises and debt forgiveness, improving its financial standing.

Next Steps

• Deploy age-gated SBX disposables in 200-300 compliance-minded retail stores in Q3 2026.
• Amend PACHA PMTAs to incorporate the IKE age-gating system.
• Introduce new 75K Puff disposable devices for SBX and Pachamama product lines, with initial orders shipping in Q2 2026.
• Form new strategic partnerships to monetize remaining PMTA-submitted PACHA synthetic nicotine products.
• Continue to amend and strengthen PMTAs with new scientific data and add age-gating functionality.
• Pursue additional strategic transactions, including potential PMTA-related asset sales.
• Continue to focus on growth in non-combustible, alternative alkaloid (non-nicotine) products.
• Advance regulatory approval efforts for the company's nicotine product portfolio.
• Continue development of intellectual property related to product access and compliance.
• Grow international sales to mitigate US regulatory risks.
• Uplift to a National Securities Exchange.

Key Dates

Recommendation

Charlies Holdings shows strong revenue growth and a narrowing net loss, indicating positive operational momentum. However, the significant regulatory uncertainties surrounding its core products, including ongoing FDA actions and the company's reliance on novel ingredients like Metatine, introduce substantial risk. While the strategic initiatives to navigate these challenges are promising, the inherent volatility and the need for further regulatory clarity warrant a cautious 'hold' stance for investors.

Keywords

Charlies Holdings, Form 10-Q, Quarterly Report, Vapor Products, Nicotine, Alternative Alkaloid, SBX, Pachamama, PACHA, PMTA, FDA, Revenue Growth, Net Loss, Financial Statements, Regulatory Compliance